顽固性心力衰竭应用米力农与美托洛尔治疗的疗效及预后分析

目的：分析顽固性心力衰竭患者应用米力农与美托洛尔联合治疗的临床疗效及预后。方法：回顾性分析76例在我院住院心功能3～4级,临床已合理用药且积极纠正心衰诱因的难治性心衰患者,按治疗方案不同分为两组：对照组,予以常规治疗,共37例;研究组,在常规治疗基础上予以米力农与美托洛尔联合治疗,共39例。治疗疗程为1月,治疗前后两组患者分别进行6 min步行试验和心脏超声检查,对比两组患者心功能改变。随访1年,比较两组患者的预后指标（再入院率、猝死率）的差异。结果：与对照组相比,研究组在6 min步行试验距离、心率、LVEF、LVd及每搏输出量上有明显改善（P〈0.05）;且研究组的预后指标（再入院率、猝死率）均小于对照组（P〈0.05）。结论：米力农与美托洛尔联合治疗难治性心衰临床疗效明显,预后明显改善。

Clinical Efficiency and Prognosis of Milrinone Plus Metoprolol to Patients with Intractable Heart Failure

Objective：To analyze the clinical efficiency and prognosis of milrinone plus metoprolol to patients with intractable heart failure.Methods：A total of 76 patients in hospital with heart function 3～4 class,rational clinical administration and correction heart failure inducement were divided into two groups,research group（be given conventional therapy,37 cases） and control group（be given conventional therapy and administration of milrinone plus metoprolol,39 cases）,according to the therapeutic schedule.The course of the treatments were all one month.The six-minute walk test and Ultrasonic Cardiogram were been performed to all patients.The indexs of heart function were been compared between two groups.After one year follow-up,the indexs of prognosis,such as readmission rate and sudden death rate,were been compared between two groups.Results：Compared to control group,the distance of six-minute walk test,heart rate,LVEF,LVd and stroke volume in research group were better（P0.05）,and the readmission rate and sudden death rate in research group were lower（P0.05）.Conclusions：The clinical efficiency of milrinone plus metoprolol to patients with intractable heart failure was more marked,and prognosis was better.